Recursion Acquires Vium Strengthening Its Attempts to Industrialize Drug Discovery
Recursion, Vium | July 29, 2020
Recursion, a digital biology company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research. Recursion’s acquisition of Vium signals continued and rapid integration of advanced technologies to grow its drug discovery pipeline of over 30 programs along with programs developed jointly with large pharmaceutical partners.
“Technology is set to change the pace, scale and cost of drug discovery over the coming decades. At Recursion, we are building a vast machine to rapidly discover drugs through the integration of technology at every step in the process,” said Chris Gibson, Ph.D., co-founder and CEO of Recursion. “Bringing the fantastic team at Vium in-house will enable us to build on our core technology and vision, augmenting our huge in vitro datasets with large, complementary in vivo datasets, and advancing our mission to decode biology to radically improve patient lives.”